Consideration on implementation of co-administration of Seasonal Influenza and COVID-19 vaccines during pandemic in China / 中华预防医学杂志

Influenza is an infectious respiratory disease caused by the influenza viruses. Older people, infants and people with underlying medical conditions could have a higher risk of severe influenza symptoms and complications. The co-infection of Coronavirus Diseases 2019 (COVID-19) with influenza viruses could lead to the complication of prevention, diagnosis, control, treatment, and recovery of COVID-19. Influenza vaccine and COVID-19 vaccine overlapped in target populations, vaccination time, and inoculation units. Although there was insufficient evidence on the immunogenicity and safety of co-administration of influenza vaccine and COVID-19 vaccine, World Health Organization and some countries recommended co-administration of inactivated influenza vaccine and COVID-19 vaccine. This review summarized domestic and international vaccination policies and research progress, and put forward corresponding suggestions in order to provide scientific support for the formulation of vaccination strategy on seasonal influenza vaccine and COVID-19 vaccine.

Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China / 中华预防医学杂志

In December 2019, novel coronavirus pneumonia epidemic occurred in Wuhan, Hubei Province, and spread rapidly across the country. In the early stages of the epidemic, China adopted the containment strategy and implemented a series of core measures around this strategic point, including social mobilization, strengthening case isolation and close contacts tracking management, blocking epidemic areas and traffic control to reduce personnel movements and increase social distance, environmental measures and personal protection, with a view to controlling the epidemic as soon as possible in limited areas such as Wuhan. This article summarizes the background, key points and core measures in the country and provinces. It sent prospects for future prevention and control strategies.

Early containment strategies and core measures for prevention and control of novel coronavirus pneumonia in China / 中华预防医学杂志

@#In December 2019, novel coronavirus pneumonia epidemic occurred in Wuhan, Hubei Province, and spread rapidly across the country. In the early stages of the epidemic, China adopted the containment strategy and implemented a series of core measures around this strategic point, including social mobilization, strengthening case isolation and close contacts tracking management, blocking epidemic areas and traffic control to reduce personnel movements and increase social distance, environmental measures and personal protection, with a view to controlling the epidemic as soon as possible in limited areas such as Wuhan. This article summarizes the background, key points and core measures in the country and provinces. It sent prospects for future prevention and control strategies.

Strengthen operational researches on influenza polices, and promote influenza vaccination in China / 中华预防医学杂志

This year of 2019 is the 10th anniversary of the 2009 H1N1 influenza pandemic, and a series of paper on epidemiology, disease burden, vaccine usage and adverse events following immunization (AEFI) incidences, cost-effectiveness of influenza vaccination, are forming an important topic of "influenza disease burden and vaccine policies" in this journal, which provide evidences and options for China's influenza prevention and control. We should continue to strengthen the operational researches on influenza prevention and control polices, increase the influenza vaccine coverage in high-risk groups, and improve the capacities of control and pandemic preparedness.

Technical guidelines for seasonal influenza vaccination in China (2018-2019) / 中华预防医学杂志

Seasonal influenza vaccination is the most effective way to prevent influenza virus infection and complications from infection. Currently, China has licensed trivalent inactivated influenza vaccine (IIV3) and quadrivalent inactivated influenza vaccine (IIV4), including split-virus influenza vaccine and subunit vaccine. Except for a few major cities, influenza vaccine is a category Ⅱ vaccine, which means influenza vaccination is voluntary, and recipients must pay for it. To strengthen the technical guidance for prevention and control of influenza and operational research on influenza vaccination in China, the National Immunization Advisory Committee (NIAC) Influenza Vaccine Technical Working Group (TWG), updated the 2014 technical guidelines and compiled the "Technical guidelines for seasonal influenza vaccination in China (2018-2019)" . The main updates in this version include: epidemiology, disease burden, types of influenza vaccines, northern hemisphere influenza vaccination composition for the 2018-2019 season, IIV3 and IIV4 immune response, durability of immunity, immunogenicity, vaccine efficacy, effectiveness, safety, cost-effectiveness and cost-benefit. The influenza vaccine TWG provided the recommendations for influenza vaccination for the 2018-2019 influenza season based on existing scientific evidence. The recommendations described in this report include the following: Points of Vaccination clinics (PoVs) should provide influenza vaccination to all persons aged 6 months and above who are willing to be vaccinated and do not have contraindications. No preferential recommendation is made for one influenza vaccine product over another for persons for whom more than one licensed, recommended, and appropriate product is available. To decrease the risk of severe infections and complications due to influenza virus infection among high risk groups, the recommendations prioritize seasonal influenza vaccination for children aged 6-59 months, adults ≥60 years of age, persons with specific chronic diseases, healthcare workers, the family members and caregivers of infants <6 months of age, and pregnant women or women who plan to become pregnant during the influenza season. Children aged 6 months through 8 years require 2 doses of influenza vaccine administered a minimum of 4 weeks apart during their first season of vaccination for optimal protection. If they were vaccinated in 2017-2018 influenza season or a prior season, 1 dose is recommended. People more than 8 years old require 1 dose of influenza vaccine. It is recommended that people receive their influenza vaccination by the end of October. Influenza vaccination should be offered as soon as the vaccination is available. For the people unable to be vaccinated before the end of October, influenza vaccination will continue to be offered for the whole season. Influenza vaccine is also recommended for use in pregnant women during any trimester. These guidelines are intended for use by staff members of the Centers for Disease Control and Prevention at all levels who work on influenza control and prevention, PoVs staff members, healthcare workers from the departments of pediatrics, internal medicine, and infectious diseases, and staff members of maternity and child care institutions at all levels.

Technical guidelines for seasonal influenza vaccination in China, 2018-2019 / 中华流行病学杂志

Seasonal influenza vaccination is the most effective way to prevent influenza virus infection and its complications.Currently,China has licensed trivalent (IIV3) and quadrivalent inactivated influenza vaccine (IIV4),including split-virus influenza vaccine and subunit vaccine.In most parts of China,influenza vaccine is a category Ⅱ vaccine,which means influenza vaccination is voluntary,and recipients need to pay for it.To strengthen the technical guidance for prevention and control of influenza and the operational research on influenza vaccination in China,the National Immunization Advisory Committee (NIAC),Influenza Vaccine Technical Working Group (TWG),updated the 2014 technical guidelines and compiled the "Technical guidelines for seasonal influenza vaccination in China (2018-2019)",based on most recent existing scientific evidences.The main updates include:epidemiology and disease burden of influenza,types of influenza vaccines,northern hemisphere influenza vaccination composition for the 2018-2019 season,and,IIV3 and IIV4 vaccines' major immune responses,durability of immunity,immunogenicity,vaccine efficacy,effectiveness,safety,cost-effectiveness and cost-benefit.The recommendations include:Points of Vaccination clinics (PoVs) should provide influenza vaccination to all persons aged 6 months and above who are willing to be vaccinated and do not have contraindications.No preferential recommendation is made for any influenza vaccine product for persons who can accept ≥ 1 licensed,recommended,and appropriate products.To decrease the risk of severe infections and complications due to influenza virus infection among high risk groups,the recommendations prioritize seasonal influenza vaccination for children aged 6-60 months,adults ≥60 years of age,persons with specific chronic diseases,healthcare workers,the family members and caregivers of infants ＜6 months of age,and pregnant women or women who plan to pregnant during the influenza season.Children aged 6 months to 8 years old require 2 doses of influenza vaccine administered a minimum of 4 weeks apart during their first season of vaccination for optimal protection.If they were vaccinated in previous influenza season,1 dose is recommended.People ≥ 9 years old require 1 dose of influenza vaccine.It is recommended that people receive their influenza vaccination by the end of October.Influenza vaccination should be offered as soon as the vaccination is available.Influenza vaccination should continue to be available for those unable to be vaccinated before the end of October during the whole season.Influenza vaccine is also recommended for use in pregnant women during any trimester.These guidelines are intended for CDC members who are working on influenza control and prevention,PoVs members,healthcare workers from the departments of pediatrics,internal medicine,and infectious diseases,and members of materuity and child care institutions at all levels.

Seasonal, avian and pandemic influenza: are we prepared? / 中华流行病学杂志

China experienced a very high and severe influenza seasonal epidemics during the past winter and spring of 2017-2018 season.This year of 2018 is the 100th anniversary of the 1918 "Spanish influenza" pandemic,a series of papers under the topic "One Hundred Years of Influenza Pandemics" are produced to demonstrate the impact,characteristics and responses of the past influenza pandemics in global and China,to review the progress and experiences of influenza surveillance,prevention and control strategies,vaccination and antivirus in China,and to discuss the gap and challenges of the prevention,control and response to the seasonal influenza,human avian influenza infection and influenza pandemics.We hope this series could help to raise the awareness of the seasonal and pandemic influenza in publics,and to improve the pandemic preparedness in China.

Technical guidelines for seasonal influenza vaccination in China, 2018-2019 / 中华流行病学杂志

Seasonal influenza vaccination is the most effective way to prevent influenza virus infection and its complications.Currently,China has licensed trivalent (IIV3) and quadrivalent inactivated influenza vaccine (IIV4),including split-virus influenza vaccine and subunit vaccine.In most parts of China,influenza vaccine is a category Ⅱ vaccine,which means influenza vaccination is voluntary,and recipients need to pay for it.To strengthen the technical guidance for prevention and control of influenza and the operational research on influenza vaccination in China,the National Immunization Advisory Committee (NIAC),Influenza Vaccine Technical Working Group (TWG),updated the 2014 technical guidelines and compiled the "Technical guidelines for seasonal influenza vaccination in China (2018-2019)",based on most recent existing scientific evidences.The main updates include:epidemiology and disease burden of influenza,types of influenza vaccines,northern hemisphere influenza vaccination composition for the 2018-2019 season,and,IIV3 and IIV4 vaccines' major immune responses,durability of immunity,immunogenicity,vaccine efficacy,effectiveness,safety,cost-effectiveness and cost-benefit.The recommendations include:Points of Vaccination clinics (PoVs) should provide influenza vaccination to all persons aged 6 months and above who are willing to be vaccinated and do not have contraindications.No preferential recommendation is made for any influenza vaccine product for persons who can accept ≥ 1 licensed,recommended,and appropriate products.To decrease the risk of severe infections and complications due to influenza virus infection among high risk groups,the recommendations prioritize seasonal influenza vaccination for children aged 6-60 months,adults ≥60 years of age,persons with specific chronic diseases,healthcare workers,the family members and caregivers of infants ＜6 months of age,and pregnant women or women who plan to pregnant during the influenza season.Children aged 6 months to 8 years old require 2 doses of influenza vaccine administered a minimum of 4 weeks apart during their first season of vaccination for optimal protection.If they were vaccinated in previous influenza season,1 dose is recommended.People ≥ 9 years old require 1 dose of influenza vaccine.It is recommended that people receive their influenza vaccination by the end of October.Influenza vaccination should be offered as soon as the vaccination is available.Influenza vaccination should continue to be available for those unable to be vaccinated before the end of October during the whole season.Influenza vaccine is also recommended for use in pregnant women during any trimester.These guidelines are intended for CDC members who are working on influenza control and prevention,PoVs members,healthcare workers from the departments of pediatrics,internal medicine,and infectious diseases,and members of materuity and child care institutions at all levels.

Seasonal, avian and pandemic influenza: are we prepared? / 中华流行病学杂志

China experienced a very high and severe influenza seasonal epidemics during the past winter and spring of 2017-2018 season.This year of 2018 is the 100th anniversary of the 1918 "Spanish influenza" pandemic,a series of papers under the topic "One Hundred Years of Influenza Pandemics" are produced to demonstrate the impact,characteristics and responses of the past influenza pandemics in global and China,to review the progress and experiences of influenza surveillance,prevention and control strategies,vaccination and antivirus in China,and to discuss the gap and challenges of the prevention,control and response to the seasonal influenza,human avian influenza infection and influenza pandemics.We hope this series could help to raise the awareness of the seasonal and pandemic influenza in publics,and to improve the pandemic preparedness in China.

Sudden increase in human infection with avian influenza A(H7N9) virus in China, September–December 2016

Since the first outbreak of avian influenza A(H7N9) virus in humans was identified in 2013, there have been five seasonal epidemics observed in China. An earlier start and a steep increase in the number of humans infected with H7N9 virus was observed between September and December 2016, raising great public concern in domestic and international societies. The epidemiological characteristics of the recently reported confirmed H7N9 cases were analysed. The results suggested that although more cases were reported recently, most cases in the fifth epidemic were still highly sporadically distributed without any epidemiology links; the main characteristics remained unchanged and the genetic characteristics of virus strains that were isolated in this epidemic remained similar to earlier epidemics. Interventions included live poultry market closures in several cities that reported more H7N9 cases recently.

Epidemiology of imported infectious diseases in China, 2013-2016 / 中华流行病学杂志

Objective To describe the epidemic of imported infectious diseases in China between 2013 and 2016, including the kinds of infectious diseases, affected provinces, source countries and the epidemiological characteristics, and provide scientific information for the prevention and control of imported infectious diseases. Methods Data of cases of imported infectious diseases in China from 2013 to 2016 were collected from national information reporting system of infectious diseases, Microsoft Excel 2010 and SPSS 18.0 were used to conduct data cleaning and analysis. Results From 2013 to 2016, a total of 16206 imported cases of infectious diseases were reported in China. Of all the cases, 83.12%(13471 cases) were malaria cases, followed by dengue fever (2628 cases,16.22%). The majority of the imported cases were males (14522 cases, 89.61%). Most cases were aged 20-50 years. Except Zika virus disease and yellow fever, which were mainly reported before and after spring festival, other imported infectious diseases mainly occurred in summer and autumn. The epidemic in affected provinces varied with the types of infectious diseases, and Yunnan reported the largest case number of imported infectious diseases, followed by Jiangsu, Guangxi and Guangdong. The imported cases were mainly from Asian countries, such as Burma, and African countries, such as Angola, Equatorial Guinea and Ghana, which also varied with the types of infectious diseases. Conclusions We should pay more attention to imported infectious diseases and strengthen the prevention and control measures in our country. In order to reduce the incidence of imported infectious diseases, the health education should be enforced for persons who plan to travel abroad and the active surveillance should be strengthened for returned travelers.

Epidemiology of imported infectious diseases in China, 2013-2016 / 中华流行病学杂志

Objective To describe the epidemic of imported infectious diseases in China between 2013 and 2016, including the kinds of infectious diseases, affected provinces, source countries and the epidemiological characteristics, and provide scientific information for the prevention and control of imported infectious diseases. Methods Data of cases of imported infectious diseases in China from 2013 to 2016 were collected from national information reporting system of infectious diseases, Microsoft Excel 2010 and SPSS 18.0 were used to conduct data cleaning and analysis. Results From 2013 to 2016, a total of 16206 imported cases of infectious diseases were reported in China. Of all the cases, 83.12%(13471 cases) were malaria cases, followed by dengue fever (2628 cases,16.22%). The majority of the imported cases were males (14522 cases, 89.61%). Most cases were aged 20-50 years. Except Zika virus disease and yellow fever, which were mainly reported before and after spring festival, other imported infectious diseases mainly occurred in summer and autumn. The epidemic in affected provinces varied with the types of infectious diseases, and Yunnan reported the largest case number of imported infectious diseases, followed by Jiangsu, Guangxi and Guangdong. The imported cases were mainly from Asian countries, such as Burma, and African countries, such as Angola, Equatorial Guinea and Ghana, which also varied with the types of infectious diseases. Conclusions We should pay more attention to imported infectious diseases and strengthen the prevention and control measures in our country. In order to reduce the incidence of imported infectious diseases, the health education should be enforced for persons who plan to travel abroad and the active surveillance should be strengthened for returned travelers.

Epidemiological characteristics of human avian influenza A (H7N9) virus infection in China / 中华流行病学杂志

<p><b>OBJECTIVE</b>To investigate the epidemiological characteristics of human infections with avian influenza A (H7N9) in China and to provide scientific evidence for the adjustment of preventive strategy and control measures.</p><p><b>METHODS</b>Demographic and epidemiologic information on human cases were collected from both reported data of field epidemiological investigation and the reporting system for infectious diseases.</p><p><b>RESULTS</b>A total of 433 cases including 163 deaths were reported in mainland China before June 4, 2014. Two obvious epidemic peaks were noticed, in March to April, 2013 and January to February, 2014. Confirmed cases emerged in 14 areas of China. Five provinces, including Zhejiang, Guangdong, Jiangsu, Shanghai, and Hunan, reported about 85% of the total cases. Median age of the confirmed cases was 58 years (range, 1-91), with 70% as males. Of the 418 cases with available data, 87% had ever exposed to live poultry or contaminated environments. 14 clusters were identified but human to human transmission could not be ruled out in 9 clusters.</p><p><b>CONCLUSION</b>Human infections with avian influenza A (H7N9) virus showed the characteristics of obvious seasonal distribution, with certain regional clusters. The majority of confirmed cases were among the elderly, with more males seen than the females. Data showed that main source of infection was live poultry and the live poultry market had played a significant role in the transmission of the virus.</p>

Relationship between early brain damage in preterm infants detected by magnetic resonance imaging and neurodevelopmental outcome / 中华围产医学杂志

Objective To investigate the relationship between early brain menifestation such as white matter damage and ventriculomegaly detected by magnetic resonance imaging(MRI) and adverse neurodevelopmental outcome in preterm infants.Methods From March 15,2007 to April 12,2011,122 preterm infants accepted MRI examination 8-14 days after birth in Chinese People's Liberation Army 202 Hospital.Totally,115 preterm infants were followed up at 12 months old and mental development index(MDI) and psychomotor development index (PDI) score were measured.MDI＜70 was as mental dysfunction,-84 as borderline dysfunction and-114 as normal; PDI＜70 was as psychomotor dysfunction,-84 as borderline dysfunction and-114 as normal.The relationship between clinical characteristics of preterm infants,MRI abnormalities and neurodevelopmental outcome were analyzed by analysis of variance,LSD and Kruskal-Wallis H test.Results The 122 premature infants included 69 males and 53 females with the median gestational age of 32 weeks(28-36 weeks)and the median birth weight of 2050 g (1270-3110 g).In 24 premature infants with mentaldysfunction,the average gestational age [(28.7 ± 1.7) weeks],birth weight[(1520.1-44.8) g] and 1 min Apgar score (5.5 ± 0.8) were all lower than those in normal infants [n =59,(33.5 ± 2.2)weeks,(2240.4 ± 47.1) g and 7.1 ± 0.8],while the average mechanical ventilation time was longer [(20.4±5.8) dvs (5.6±2.7) d](t=2.37,2.49,2.13 and 2.44,P＜0.05).In 20 premature infants with psychomotor dysfunction,the average gestational age [(27.9 ±± 1.4) weeks],birth weight [(1515.6±43.7) g],1 min Apgar score (5.6t0.5) were lower than those in normal infants [n=62,(33.2±2.4) weeks,(2264.3±42.5) g and 7.2±0.6],while the mechanical ventilation time was longer [(18.2±4.7) dvs (5.3±2.2) d](t=2.28,2.52,2.09 and 2.38,P＜0.05).Among thirteen preterm infants with severe white matter damage,eleven and nine developed mental or psychomotor dysfunction respectively.Among eleven preterm infants with moderate and severe ventriculomegaly,seven and six developed mental or psychomotor dysfunction respectively.The more severe the white matter damage and ventriculomegaly,the higher the incidence of mental (H=16.23 and 14.33,P＜0.05) and psychomotor dysfuction (H =18.63 and 12.69,P ＜ 0.05).Conclusions White matter damage is common in preterm infants.Prognosis of preterm infants with mental and psychomotor dysfunction is related with the degree of white matter damage and ventriculomegaly.

Characterization of hand, foot, and mouth disease in China between 2008 and 2009 / 生物医学与环境科学（英文）

<p><b>OBJECTIVE</b>To investigate the epidemiological and clinical features of hand, foot and mouth disease (HFMD) since several outbreaks of HFMD caused by enteroviruses were documented in China between 2007 and 2008.</p><p><b>METHODS</b>HFMD cases reported to the National Infectious Disease Information Management System database between May 2008 and April 2009 were assessed. Clinical features in some of the severe and fatal cases were analyzed the etiology of the outbreaks was investigated.</p><p><b>RESULTS</b>89.1% of reported HFMD cases were found in children<5 year-old with an age-specific incidence rate of 834.1/100 000 in the first year as the notifiable disease in China from May 2008 to April 2009. The incidence, mortality and percentage of severe cases were studied for three regions of China and found to be highest in the central region. The incidence of severe cases and mortality in rural population were significantly higher than those in urban population. Among the laboratory confirmed EV17 positive cases there were 52.6% mild, 83.5% severe, and 96.1% fatal cases. More myoclonic jerks were found in the severe case group than in group that died. Tachypnea, lip purpling, pink foaming and low limb temperature occurred more frequently in the fatal cases than in the severe cases.</p><p><b>CONCLUSION</b>The epidemic of HFMD in China was characterized predominantly by EV71 infections, had relatively high mortality rates especially in the central region, and was most prevalent in young, rural populations.</p>

The Meta Analysis on the Safety and Immunogenicity of Domestic and Imported Split Influenza Virus Vaccines / 中国疫苗和免疫

Objective To compare the safety and immunogenicity between domestic and imported,imported and imported split influenza virus vaccine in Chinese population. Methods The published studies during January 1996 and June 2008 on the comparison between split influenza virus vaccine were screened and evaluated.The meta analysis was performed on safety and immunogenicity using fixed model or random model according the heterogeneity of the studies. Results 12 studies which were all random controlled trials between split vaccine were included.10 trials were between domestic and imported vaccine,and 2 trials were between imported and imported vaccine.For 10 domestic and imported vaccine trials,the local reaction pooled OR=0.81,95% CI (0.59,1.11);the systemic reaction the pooled OR=0.78,95% CI (0.50,1.03);the H1N1 subtype seroconversion pooled OR= 0.94,95% CI (0.78,1.14);the H3N2 subtype seroconversion pooled OR =1.01,95% CI (0.87,1.17);the B type seroconversion total OR= 1.35,95% CI (0.98,1.85).For 2 imported and imported vaccine trials,the local reaction pooled OR = 1.19,95% CI (0.60,2.37);the systemic reaction the pooled OR =1.15,95% CI (0.71,1.87);the H1N1 subtype seroconversion pooled OR= 1.27,95% CI (0.37,4.37);the H3N2 subtype seroconversion pooled OR= 1.29,95% CI (0.39,4.33);the B type seroconversion pooled OR= 0.95,95% CI (0.46,1.37). Conclusions There were no statistical difference on the safety and immunogenicity between domestic and imported,imported and imported split influenza vaccine in Chinese population.

Studies on the safety and immunogenicity of lyophilized live attenuated measles-mumps-rubella combined vaccine / 中华流行病学杂志

<p><b>OBJECTIVE</b>To study the safety and immunogenicity of the measles-mumps-rubella combined vaccine (MMR) produced by Beijing Biological Product Institute.</p><p><b>METHODS</b>Children aged 10-12 years, 2-2.5 years and 8-12 months were selected to be vaccinated with Beijing MMR vaccine (test vaccine). Other groups of children with similar nature were vaccinated with measles vaccine, mumps vaccine and rubella vaccine while using imported MMR vaccine (control vaccine) as controls.</p><p><b>RESULTS</b>The safety of the Beijing MMR vaccine was confirmed after vaccinating 32 children above 2 years old. Among 104 children of 8-12 months were vaccinated with Beijing MMR vaccine, only 6.7% of the children had transient fever and 1.9% had signs of rashes but with no other signs observed. The positive seroconversion rates of measles, rubella and mumps anti-HI were 100%, 100% and 85.7% respectively. GMT also showed high lever.</p><p><b>CONCLUSION</b>The MMR vaccine (Beijing) had good safety and immunogenicity which might be used to be the bases enhance immunization of measles.</p>